Investing.com -- Genmab A/S (CSE:GMAB) shares fell more than 3% on Monday after new data from Johnson & Johnson ’s amivantamab suggested the drug could rival Genmab and Merus N.V. ’s petosemtamab in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback